TG Therapeutics

TG Therapeutics

Yahoo Finance • 22 days ago

TG Therapeutics down 11% following Q2 bottom line miss

[Second Quarter Q2 Profits Stock Trading Chart 3D Background] filo * TG Therapeutics is down ~11% in Monday trading after reporting Q2 EPS that missed expectations. * Diluted EPS of $0.05 compares to $0.17 in the year-ago period. *... Full story

Yahoo Finance • 22 days ago

Why This Top-Notch Trio Of Biotech Stocks Just Took A Tumble

Top-notch biotech stocks TG Therapeutics and Twist Bioscience took a tumble Monday on mixed second-quarter reports. Continue Reading... Full story

Yahoo Finance • 25 days ago

TG Therapeutics Q2 2026 Earnings Preview

* TG Therapeutics (TGTX [https://seekingalpha.com/symbol/TGTX]) is scheduled to announce Q2 earnings results on Monday, August 3rd, before market open. * The consensus EPS Estimate is $0.44 [https://seekingalpha.com/symbol/TGTX/earning... Full story

Yahoo Finance • 27 days ago

TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 3, 2026, at 8:30 AM ET to discuss results for the second quarter 2026 and to provide a... Full story

Yahoo Finance • last month

Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm

NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of TG Therapeutics, Inc. (NASDAQ: TGTX) breached their fiduciary duties to shareholde... Full story

Yahoo Finance • 2 months ago

2 Fast-Growing Pharmaceutical Stocks to Buy Now

Key Points Incyte has added to its pipeline through acquisitions. It anticipates four new approvals and launches through 2027. TG Therapeutics' shares are up more than 90% so far this year.10 stocks we like better than Incyte › Incyte(NA... Full story

Yahoo Finance • 2 months ago

TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia

NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant schizophrenia. The Ph... Full story

Yahoo Finance • 2 months ago

The Quest to Repair What Multiple Sclerosis Takes Away

AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people a... Full story

Yahoo Finance • 2 months ago

Is TG Therapeutics, Inc. (TGTX) A Good Stock To Buy Now?

Is TGTX a good stock to buy? We came across a bullish thesis on TG Therapeutics, Inc. on TradersPro's Substack. In this article, we will summarize the bulls' thesis on TGTX. TG Therapeutics, Inc.'s share was trading at $50.54 as of June 16... Full story

Yahoo Finance • 2 months ago

TG Therapeutics Stock Is On A Hot Streak: Why It's Up 70% And Climbing

TG Therapeutics stock is on an absolute rampage, climbing 70% in roughly the first six months of the year, as the biotech takes on Roche. Continue Reading... Full story

Yahoo Finance • 3 months ago

Why This IBD Stock Of The Day, A Roche Rival, Just Broke Out To A Four-Year High

TG Therapeutics is Wednesday's IBD Stock Of The Day. Shares broke out as the relative strength line hit a new high. Continue Reading... Full story

Yahoo Finance • 3 months ago

Dow Jones Futures Tumble As Trump Says Iran Will 'Have To Pay The Price'; CPI Inflation On Tap

Futures fell as President Trump said Iran will "have to pay the price" for taking too long to reach a deal. The CPI inflation report is on tap. Continue Reading... Full story

Yahoo Finance • 3 months ago

TG Therapeutics Announces Positive Data From BRIUMVI Study, Initiates Phase 2 Trial; Stock Gains

(RTTNews) - Tuesday, TG Therapeutics, Inc. (TGTX) announced positive topline Phase 1 data for BRIUMVI in patients with myasthenia gravis, a chronic autoimmune neuromuscular disease. At Week 24, 82 per cent of patients who received BRIUMVI... Full story

Yahoo Finance • 3 months ago

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

Treatment with BRIUMVI reduced annualized relapse rate by 56.7% vs. teriflunomide in treatment-naïve patients BRIUMVI demonstrated significant improvements across disability, MRI outcomes, and no evidence of disease activity (NEDA-3) in t... Full story

Yahoo Finance • 3 months ago

Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More

Soleus Capital Management disclosed a significant buy of Vericel(NASDAQ:VCEL), adding 1,785,079 shares in the first quarter—an estimated $63.40 million trade based on quarterly average pricing—according to a May 14, 2026, SEC filing. What... Full story

Yahoo Finance • 3 months ago

TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in adults with relapsing forms of multiple sclerosis (R... Full story

Yahoo Finance • 4 months ago

Dow Jones Futures: Stock Market Hits Highs On Iran-Deal Hopes; Nvidia Leads New Buys; ARM Flexes On Earnings

The S&P 500 and Nasdaq hit new highs on Iran deal hopes. Nvidia leads new buys with Arm a big earnings winner late. Continue Reading... Full story

Yahoo Finance • 6 months ago

BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX)

TG Therapeutics Inc. (NASDAQ:TGTX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 26, TG Therapeutics Inc. (NASDAQ:TGTX) reported Q4 revenue of $192.6 million compared with consensus estimates of... Full story

Yahoo Finance • 6 months ago

How Investors Are Reacting To TG Therapeutics (TGTX) Adding Azer-cel Milestone to Its MS Portfolio

In early March 2026, Precision BioSciences announced it hit a clinical milestone under its license with TG Therapeutics for azercabtagene zapreleucel in progressive multiple sclerosis, triggering a US$7.5 million payment that combines US$5... Full story

Yahoo Finance • 6 months ago

Soleus Adds a Significant Number of Celcuity Shares

Key Points Soleus increased its Celcuity stake by 629,398 shares. The firm held over 1.8 million shares at the end of the quarter. Celcuity now accounts for 6.7% of fund AUM10 stocks we like better than Celcuity › On Feb. 12, Soleus Capi... Full story